As the global Coronavirus crisis continues to escalate, the need to find a solution is greater than ever.  We are proud to announce that Almac is also playing our part in the fight against the COVID-19 pandemic.

We have now commenced work on supporting eleven separate crucial research projects into COVID-19 treatment options for a variety of global pharmaceutical, biotech and research institutions.  In addition, we are currently in discussions with clients on how we can support an additional twenty-two programmes.

We are supporting this urgent research need through a range of services across our Business Units, including analytical services, peptide development, expedited Interactive Response Technology (IRT) support and clinical trial manufacturing, packaging and distribution. 

These vital projects cover a range of different areas including vaccines and various potential treatments for symptoms and the effects of this disease.

In addition to this immediate research support, Almac continues to directly contribute to key operations in the supply chain of hundreds of life-saving drugs in a wide variety of therapeutic areas including oncology, neurology, pain management and cardiovascular.

In order to ensure we can support this vital work, in each territory where Almac operates and classification has been defined by local authorities, we are recognised as an “essential” or “life-sustaining” business due to the essential nature of the work we carry out.

Almac continues to conduct critical business operations and our dedicated, skilled employees will continue to support these critical supply chains.

To find out more about how Almac can support your project please contact us and we will be happy to discuss your specific requirements.

This website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies